{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:23:39Z","timestamp":1792664619651,"version":"4.5.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Sleep represents a major frontier both in clinical myology and as a new possibility for delivering treatment to neuromuscular patients since various neuromuscular cases present a variable degree of disordered sleep and such conditions should be diagnosed and prevented, i.e., sleep apnea and hypoxemia. These sleep disorders are present in dystrophinopathies and in various types of limb-girdle muscular dystrophies (LGMD). Excessive daytime sleepiness (EDS) is found in patients affected by spastic paraparesis or cerebellar ataxia but is rather common in both myotonic dystrophy type 1 and 2, and the correction of sleep disorders is therefore important to improve their daily quality of life (QoL) and consequent daily functioning. Other types of sleep dysfunction such as insomnia, a reduction in rapid eye movement (REM) sleep, loss of normal REM, or sleep-disordered breathing are found in other disorders including myasthenia, ataxias, spastic paraparesis, Charcot\u2013Marie\u2013Tooth disease, and neurogenic disorders, including polyneuropathies, and need appropriate treatment. Research done on this topic aims to incorporate a variety of nuances in metabolic disorders such as those in late-onset Pompe disease and are such as those in late-onset Pompe disease who are susceptible to enzyme replacement therapy (ERT). The overarching goal is to explore both the diagnosis and methodology of sleep-related problems in both genetic and acquired neuromuscular disorders. We also review the type of available treatment opportunities utilized to improve neuromuscular patients\u2019 QoL.<\/jats:p>","DOI":"10.3389\/fneur.2023.1195302","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T16:48:55Z","timestamp":1688057335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The role of sleep in neuromuscular disorders"],"prefix":"10.3389","volume":"14","author":[{"given":"Corrado I.","family":"Angelini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Ansevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Siciliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S1474-4422(12)70204-1","article-title":"The myotonic dystrophies: molecular, clinical, and therapeutic challenges","volume":"11","author":"Udd","year":"2012","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.gene.2013.03.059","article-title":"Myotonic dystrophy type 1 (DM1): a triplet repeat expansion disorder","volume":"522","author":"Kumar","year":"2013","journal-title":"Gene"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/ejhg.2012.108","article-title":"Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2","volume":"20","author":"Kamsteeg","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1590\/S0004-282X2011000200021","article-title":"Sleep disorders in cerebellar ataxias","volume":"69","author":"Pedroso","year":"2011","journal-title":"Arq Neuropsiquiatr"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.nmd.2014.02.005","article-title":"Plasma microRNAs as biomarkers for myotonic dystrophy type 1","volume":"24","author":"Perfetti","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1089\/hum.2012.212","article-title":"Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy","volume":"24","author":"Gao","year":"2013","journal-title":"Hum Gene Ther"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1055\/s-0032-1329202","article-title":"Myotonic dystrophy: from bench to bedside","volume":"32","author":"Johnson","year":"2012","journal-title":"Semin Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1212\/WNL.0b013e3181dc1a3a","article-title":"Mexiletine is an effective anti-myotonia treatment in myotonic dystrophy type 1","volume":"74","author":"Logigian","year":"2010","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1212\/WNL.56.6.794","article-title":"Modafinil for excessive daytime sleepiness in myotonic dystrophy","volume":"56","author":"Damian","year":"2001","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1136\/jnnp.2008.162594","article-title":"Risk of arrhythmia in type I myotonic dystrophy: the role of clinical and genetic variables","volume":"80","author":"Cudia","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3109\/09638288.2012.754952","article-title":"Effects of hand-training in persons with myotonic dystrophy type 1\u2013A randomized controlled cross-over pilot study","volume":"35","author":"Aldehag","year":"2013","journal-title":"Disabil Rehabil"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/ana.20460","article-title":"Aerobic training in patients with myotonic dystrophy type 1","volume":"57","author":"Orngreen","year":"2005","journal-title":"Ann Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1743-0003-10-94","article-title":"Chronic muscle stimulation improves muscle function and reverts the abnormal surface EMG pattern in myotonic dystrophy: a pilot study","volume":"10","author":"Chisari","year":"2013","journal-title":"J Neuroeng Rehabil"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"CD003907","DOI":"10.1002\/14651858.CD003907.pub3","article-title":"Strength training and aerobic exercise training for muscle disease","volume":"1","author":"Voet","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"0274970","DOI":"10.1371\/journal.pone.0274970","article-title":"Objective and subjective measures of sleep in men with muscular dystrophy","volume":"17","author":"Morse","year":"2022","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pedneo.2022.09.016","article-title":"Respiratory phenotypes of neuromuscular diseases: a challenging issues for pediatricians","volume":"64","author":"Borrelli","year":"2023","journal-title":"Pediatr Neonatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.nmd.2022.02.003","article-title":"Clinical and neuroradiological correlates of sleep in myotonic dystrophy type 1","volume":"32","author":"Hamilton","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1159\/000342895","article-title":"Sleep disturbances in myotonic dystrophy type 2","volume":"68","author":"Shepard","year":"2012","journal-title":"Eur Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"9798","DOI":"10.4081\/ejtm.2021.9798","article-title":"Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC consortium","volume":"31","author":"Angelini","year":"2021","journal-title":"Eur J Transl Myol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S1474-4422(16)30231-9","article-title":"Carpal tunnel syndrome: clinical features, diagnosis, and management","volume":"15","author":"Padua","year":"2016","journal-title":"Lancet Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1195302\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T16:48:57Z","timestamp":1688057337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1195302\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":20,"alternative-id":["10.3389\/fneur.2023.1195302"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1195302","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"article-number":"1195302"}}